ADDITIONAL INFORMATION CONTINUED REMUNERATION OF DIRECTORS 2025 Salary/fees $ Bonus $ Super– annuation $ Share based payments $ Total $ Non–Executive Directors Patrick Davies 170,023 – 19,977 – 190,000 Dianne Angus 89,486 – 10,514 – 100,000 Dr Jenny Harry 93,960 – 11,040 – 105,000 Joe Basile 93,960 – 11,040 – 105,000 447,429 – 52,571 – 500,000 Executive Directors Jon Pilcher 807,534 – 29,966 789,5151 1,627,015 Total 1,254,963 – 82,537 789,515 2,127,015 1 In May 2025, the Board resolved to issue options for Jon Pilcher to acquire 360,000 ordinary shares, which are subject to shareholder approval and will not be issued prior to receiving approval at a future meeting of shareholders. As the services received from Jon Pilcher in respect of the proposed grant of options have commenced, the fair value of the share options has been estimated using the Black-Scholes model. The fair value estimate will be revised once the grant date has been established, subject to shareholder approval. 2024 Salary/fees $ Bonus $ Super– annuation $ Share based payments $ Total $ Non–Executive Directors Patrick Davies 157,500 – – – 157,500 Dr Trevor Scott (retired 30 June 2024) 37,500 – – – 37,500 Dianne Angus 78,627 – 8,873 – 87,500 Dr Jenny Harry 80,869 – 9,131 – 90,000 Joe Basile 90,000 – – – 90,000 444,496 – 18,004 – 462,500 Executive Directors Jon Pilcher 621,334 – 28,665 18,402 668,402 Total 1,065,830 – 46,670 18,402 1,130,902 Neuren Pharmaceuticals Limited Annual Report 2025 60
RkJQdWJsaXNoZXIy MjE2NDg3